YIRUI Pharmaceutical Technology

, Ltd. was founded in 2018 in Hangzhou, China. The company focuses on the research and development of targeted drugs. The founder, Xiaolu Wang, has a background in pharmaceuticals, although no prior companies are specified., Ltd. specializes in the research and development of small molecule innovative targeted drugs, focusing primarily on therapeutic solutions for autoimmune diseases, diabetic complications, and chronic inflammatory conditions. Their main product, YR-001, is currently in Phase II clinical trials in the United States and is designed to address autoimmune skin diseases, which have significant unmet medical needs. The company adopts a strategic approach to drug development that emphasizes the integration of basic research with clinical application, ensuring timely transformations of research outcomes into market-ready products. The company generates revenue through strategic partnerships and collaborations with various stakeholders, including research institutions and investment firms. These collaborations often involve co-development agreements and licensing arrangements for their innovative drugs, particularly YR-001 and other pipeline products. Although specific pricing structures for products and services have not been disclosed, the company’s revenue model is expected to involve B2B transactions, with potential collaborations leading to shared revenues from successful drug approvals and sales., Ltd. YIRUI plans to further develop new products targeting additional autoimmune conditions and expand its market presence, particularly in regions with high medical needs, leveraging the recent funds to support these initiatives.

1. Series A

   Dec 19, 2023

   Amount

   Undisclosed

   Investors

   Locked